<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000776.v1.p1" parentStudy="phs000776.v1.p1" createDate="2014-07-09" modDate="2014-07-09">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Kelly A. Frazer</td><td>Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA</td></tr>
		<tr><td>Co-Investigators</td><td>Peter J. Shepard</td><td>Department of Pediatrics and Rady Children&#39;s Hospital, University of California San Diego, La Jolla, CA, USA</td></tr>
		<tr><td>Co-Investigators</td><td>Bruce A. Barshop</td><td>Department of Pediatrics and Rady Children&#39;s Hospital, University of California San Diego, La Jolla, CA, USA</td></tr>
		<tr><td>Co-Investigators</td><td>Matthias R. Baumgartner</td><td>Division of Metabolic Diseases and Children&#39;s Research Center, University Children&#39;s Hospital, Zurich, Switzerland</td></tr>
		<tr><td>Co-Investigators</td><td>John-Bjarne Hansen</td><td>Department of Clinical Medicine, University of Troms&#248;, Troms&#248;, Norway</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Consanguinity and Rare Mutations Outside of MCCC Genes Underlie Non-Specific Phenotypes of MCC Deficiency</StudyNameEntrez>
	<StudyNameReportPage>Consanguinity and rare mutations outside of MCCC genes underlie non-specific phenotypes of MCC Deficiency</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>3-Methylcrotonyl-CoA Carboxylase Deficiency (MCCD) is an autosomal recessive disorder of leucine catabolism, which has a highly variable clinical phenotype, ranging from acute metabolic acidosis to non-specific symptoms such as developmental delay, failure to thrive, hemiparesis, muscular hypotonia, and multiple sclerosis. Implementation of newborn screening for MCCD has resulted in broadening the range of phenotypic expression to include asymptomatic adults. The purpose of this study was to identify factors underlying the varying phenotypes of MCCD.</p> <p>We performed exome sequencing on DNA from 107 healthy controls and 33 cases. We examined these data for associations between either MCC mutational status, genetic ancestry or consanguinity and the absence or presence/specificity of clinical symptoms in MCCD cases. We determined that individuals with non-specific clinical phenotypes are highly inbred compared to cases that are asymptomatic and healthy controls. For five of these individuals we discovered a homozygous damaging mutation in a disease gene that is likely to underlie their non-specific clinical phenotypes previously attributed to MCCD.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>The 33 MCCD cases were determined to have a very profound deficiency of MCC.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Shepard PJ, Barshop BA, Baumgartner MR, Hansen J, Jepsen K, Smith EN, Frazer KA" title="Consanguinity and rare mutations outside of MCCC genes underlie nonspecific phenotypes of MCC Deficiency" journal="Under review"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Urea Cycle Disorders, Inborn"/>
		<Disease vocab_source="MESH" vocab_term="IGHMBP2 protein, human"/>
		<Disease vocab_source="MESH" vocab_term="ALDH7A1 protein, human"/>
		<Disease vocab_source="MESH" vocab_term="CFTR protein, human"/>
		<Disease vocab_source="MESH" vocab_term="TTC37 protein, human"/>
		<Disease vocab_source="MESH" vocab_term="aarF domain containing kinase 4, human"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Kelly A. Frazer</AttName>
			<Institution>Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Peter J. Shepard</AttName>
			<Institution>Department of Pediatrics and Rady Children&#39;s Hospital, University of California San Diego, La Jolla, CA, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Bruce A. Barshop</AttName>
			<Institution>Department of Pediatrics and Rady Children&#39;s Hospital, University of California San Diego, La Jolla, CA, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Matthias R. Baumgartner</AttName>
			<Institution>Division of Metabolic Diseases and Children&#39;s Research Center, University Children&#39;s Hospital, Zurich, Switzerland</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>John-Bjarne Hansen</AttName>
			<Institution>Department of Clinical Medicine, University of Troms&#248;, Troms&#248;, Norway</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Kristen Jepsen</AttName>
			<Institution>Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA</Institution>
		</Header>
		<Header title="Co-Investigators">
			<AttName>Erin N. Smith</AttName>
			<Institution>Department of Pediatrics and Rady Children&#39;s Hospital, University of California San Diego, La Jolla, CA, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Genetic Factors Involving Expression of 3-Methylcrotonyl-CoA Carboxylase Deficiency (5R03HD69983)</AttName>
			<Institution>National Institute of Child Health and Development, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>SNFS-3200AO-109219/1</AttName>
			<Institution>Swiss National Science Foundation, Lausanne, Switzerland</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyHistory><![CDATA[
<p>There is not currently a history for this study.</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-MCCD-IRB-NPU" longName="Disease-Specific (3-Methylcrotonyl-CoA Carboxylase Deficiency, IRB, NPU)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NICHD</DacName>
      <DacFullName>NICHD-DAC</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000776.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>yes</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000776.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000776.v1.p1" FileName="Frazer_MCCD_Study-DUC.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (3-Methylcrotonyl-CoA Carboxylase Deficiency, IRB, NPU)</ConsentName>
        <ConsentAbbrev>DS-MCCD-IRB-NPU</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to 3-Methylcrotonyl-CoA Carboxylase Deficiency. Requestor must provide documentation of local IRB approval. Use of the data is limited to not-for-profit organizations.</UseLimitation>
        <IrbRequired>Yes</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
